Parallel Scientific Advice 101

FDA-EMA Parallel Scientific Advice (PSA) Program

Presented by Anabela Marcal on 16 March 2022
EMA Liaison Official to FDA
Webinar Objectives

- Provide an overview of the Parallel Scientific Advice (PSA) program. Participants will gain a general understanding including how to submit a PSA request, the expected procedure timeline, and outcomes.
- Examine findings from a 5-year PSA program review and gain insights into the PSA process by reviewing case studies.
- Understand best practice recommendations for those considering a PSA request.
PSA 101 - Agenda

• What is Parallel Scientific Advice (PSA)
• Overview of EMA-FDA collaboration
• PSA Method
• Sponsor submission to the Agencies
What is PSA

A mechanism where EMA and FDA concurrently exchange their views on scientific issues with the sponsor

– Increase dialogue early in product lifecycle
– Deepen understanding of regulatory decisions
– Optimize development
– Avoid unnecessary testing

Conducted under Confidentiality Commitments

The best candidates for PSA

• important medicinal products (unmet medical needs)
• indications lacking development guidelines, or significantly different guidelines
PSA

- **Voluntary**, at request of sponsor
- Questions on product development put both to EMA and FDA
- Scientific advice can be provided on **any scientific question**
- Advice can be asked only for a specific part of the development
- Discussions between EMA-FDA, and joint discussion with sponsor
- Agencies issue own responses to sponsor’s questions in line with usual procedures
Will a PSA request be granted?

- A PSA request does not guarantee the PSA procedure will be granted

- For various reasons, one or both agencies may decline to participate in such a procedure

- If request not granted:
  - Sponsor can still pursue a Scientific Advice (SA) procedure with each Agency individually
  - Or consultative advice *(experts from one Agency will be invited to participate in the discussions of the other)*
Overview of Collaboration

- Review of Scientific Questions [Individual Agency]
- Bilateral Meeting [EMA – FDA]
- Trilateral Meeting [Sponsor-FDA-EMA]
- Issue Feedback to Sponsor [Individual Agency]

The overall process for PSA is aligned with CHMP Scientific Advice (SA) procedure and timeline for Type B Meeting at FDA.
Standard Method for Scientific Advice

Sponsor

FDA

FDA Advice

EMA

EMA Advice
PSA Method

Meeting between FDA and EMA

Trilateral Meeting

Sponsor

Trilateral Meeting
PSA Method
What gets submitted to the Agencies?

- the product in development
- why a discussion with both FDA and EMA would be beneficial
- specific questions requiring clarification
- desired goals for the meeting
- explicit authorization for the agencies’ comprehensive exchange of all information relevant to the product

A single “Request for PSA” letter sent to both FDA and EMA

- Email: emainternational@ema.europa.eu
- Email: US-FDA-EUR@fda.hhs.gov
Why PSA?

- Opportunity for engagement with both regulatory agencies
- Avoid duplication of work
- Common approach where feasible or better understanding of the reasons for potentially remaining divergences

‘Both agencies will strive to provide PSA responses that are convergent’ (PSA General Principles)

- Opportunity to simultaneously solicit and receive “official” feedback
Resource for Applying for PSA

General Principles for PSA document:

https://www.fda.gov/media/105211/download

Further information

Anabela.marcal@ema.europa.eu
emainternational@ema.europa.eu

Send us a question  Go to www.ema.europa.eu/contact

Follow us on  @EMA_News
5-Year Program Review and “Myth-busting” the PSA Timeline

LCDR Shannon Thor, PharmD, MS
International Policy Analyst, Europe Office
Office of Global Policy and Strategy
PSA Five Year Review: 2017-2021

<table>
<thead>
<tr>
<th>Category</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Requests</td>
<td>37</td>
</tr>
<tr>
<td>Accepted Requests</td>
<td>26 (70%)</td>
</tr>
<tr>
<td>Withdrawn/Package not Submitted</td>
<td>4 (15%)</td>
</tr>
<tr>
<td>Completed Procedures</td>
<td>22</td>
</tr>
</tbody>
</table>
PSA Five Year Review: 2017-2021

PSA Submissions by Year
2017-2021

<table>
<thead>
<tr>
<th>Year</th>
<th>Requested</th>
<th>Accepted</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td>4</td>
<td>9</td>
</tr>
<tr>
<td>2019</td>
<td>4</td>
<td>6</td>
</tr>
<tr>
<td>2020</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>2021</td>
<td>10</td>
<td>7</td>
</tr>
</tbody>
</table>
PSA Five Year Review: 2017-2021

ACCEPTED PSA BY PRODUCT CATEGORY

N=26

- Gastroenterology/Inborn Errors/Rare Diseases/Medical Genetics: 23%
- Oncology: 15%
- Neurology: 8%
- Cardiology and Nephrology: 12%
- Anti-infectives: 15%
- Other: 27%
- Other: 27%
REASONS FOR DENIALS (N=11)

- Medical device component (4)*
  * Device component is NOT an automatic denial
- Timing too early in development (4)
- Other (3)
Myth #1: PSA takes too long!

Myth #2: PSA timelines are unpredictable

Myth-busting the Timeline
Myth-busting the Timeline

Examined Cohort of 2020 PSA Procedures using EMA data

- How long to accept informal request?
- How long from request acceptance to validation?
- How long from validation to Final Advice Letter?
Myth #1: PSA Takes Too Long

MYTH-BUSTED!

Average time to acceptance: **13 calendar days**
- By contrast, CDER’s Type B meeting requests are allowed 21 days for review

Average time from meeting package validation to advice letter (EMA): **79 days**
- Published PSA Timeline reference is 75 days
Myth #2: PSA Timeline Unpredictable

MYTH-BUSTED!

- 2020 cohort data shows that the published PSA timeline is highly predictable once the meeting package is validated.

- Greatest variability is in the validation phase when the Applicant has increased control of the timeline:
  - Average 67 days from acceptance to validation.
  - May request a pre-submission meeting with EMA.
  - May have to address deficiencies in package.
  - May have strategic reasons for delaying submission.
## PSA Timeline*

<table>
<thead>
<tr>
<th>Day</th>
<th>FDA</th>
<th>EMA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anytime</td>
<td>Sponsor submits informal request for Parallel Scientific Advice to FDA and EMA; Agencies decline → no PSA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Agencies accept → Sponsor begins drafting meeting package according to SAWP procedures</td>
<td></td>
</tr>
<tr>
<td>Day -1 to -45</td>
<td>Meeting Package Submission and Validation Phase; Option for preparatory meeting with EMA according to SAWP procedures</td>
<td></td>
</tr>
<tr>
<td><strong>Day 0</strong></td>
<td>FDA receives validated meeting package</td>
<td>EMA validates meeting package</td>
</tr>
<tr>
<td>Day 5</td>
<td></td>
<td>EMA procedure begins (SAWP1)</td>
</tr>
<tr>
<td>Day 15-25</td>
<td>FDA internal meeting</td>
<td>EMA SAWP internal discussion</td>
</tr>
<tr>
<td>Day 30-34</td>
<td>FDA sends Preliminary Comments to EMA</td>
<td>EMA sends List of Issues to FDA</td>
</tr>
<tr>
<td>Day 35</td>
<td>Bilateral FDA/EMA meeting (SAWP2)</td>
<td>Bilateral FDA/EMA meeting (SAWP2)</td>
</tr>
<tr>
<td>Day 65</td>
<td>Trilateral Sponsor/FDA/EMA meeting (SAWP3)</td>
<td>Trilateral Sponsor/FDA/EMA meeting (SAWP3)</td>
</tr>
<tr>
<td>Day 75 to 95</td>
<td>FDA issues final meeting minutes (30 days after trilateral)</td>
<td>EMA issues final advice letter (10 days after trilateral)</td>
</tr>
</tbody>
</table>

*PSA does not follow PDUFA or BSuFA meeting timelines. Preparatory time to initiate process is 2-3 months; schedule above is an estimate. Scheduled meetings correspond to Scientific Advice Working Party (SAWP) meeting schedule.
FDA/EMA Parallel Scientific Advice (PSA) - Two case studies

FDA/EMA Parallel Scientific Advice - Webinar

Presented by Thorsten Vetter, MD
Senior Scientific Officer, Scientific Advice Office, European Medicines Agency (EMA)
Agenda

Two anonymised recent PSA cases:

• PSA request letter – elements which supported PSA acceptance
• Topics raised for discussion
• Procedural flow/experience
• Sponsor feedback for Case 1
• Involvement of EMA Committees/Working Parties/Patients for Case 2
Background and PSA request letter

- Small molecule immunomodulator - treatment of IBD
  
  change of previously agreed paediatric development

- Request letter described the challenge:
  
  - rare sub-population
  - inability to recruit sufficient adolescent patients in a Phase 3 study

- Development discussed previously with both FDA and EMA
  
  - agreed EMA Paediatric Investigation Plan (PIP)
  - Agreed FDA Initial Paediatric Study Plan (iPSP)
Expected PSA benefits:

- Facilitate globally harmonised approach to evidence generation in the paediatric population
- Facilitate amendments to agreed PIP (EMA) and iPSP (FDA)
- New extrapolation based proposal had been informally and independently discussed with FDA and EMA experts and views were divergent

Clear objective for PSA:

- Trilateral discussion on paediatric development programme acceptable to FDA and EMA in an area of unmet medical need
Questions raised

- Focus on the design of a new Phase 2/3 safety, efficacy, PK and PD study in the paediatric population:
  - study population
  - age cohorts
  - endpoints
  - sample size
  - statistical analysis plan
  - safety monitoring

- ‘FDA-only’ question on the amendment of the iPSP

- ‘EMA-only’ question on the overall paediatric evidence generation plan to support benefit/risk assessment in the EU
Case 1

Procedural flow – acceptance to start of procedure

- PSA acceptance 10 days after request letter submission
- The sponsor *immediately* communicated envisaged procedural timelines
- FDA and EMA procedural leads convened a call and agreed on procedural timelines
- 6 weeks after acceptance, the draft package received for EMA validation review, no preparatory meeting requested
- 10 weeks after acceptance the package was validated
Procedural flow – start to trilateral meeting

- The published PSA timelines were met
- FDA/EMA bilateral meeting 5 weeks after procedure start
- EMA List of Issues provided 2 weeks before the trilateral meeting
- FDA preliminary answers provided 1 week before the trilateral meeting
- Sponsor considered the preliminary feedback from both Agencies and integrated into a trilateral meeting presentation as well as providing written answers
Procedural flow – trilateral meeting to written advice

- Trilateral meeting 8 weeks after start of the procedure
- Sponsor drives trilateral meeting - integrating and prioritising issues raised by both Agencies to make best use of the 90 min meeting
- After the trilateral meeting, FDA and EMA have a 30 min debriefing discussion
- Sponsor provided minutes 4 days after the meeting
- EMA Final Advice Letter shared 10 weeks after procedure start
- Time from PSA request to Final Letter: 20 weeks
- Final advice letters are exchanged between Agencies for information
Case 1

PSA **benefits** based on Sponsor feedback

- Preparation of single meeting package saved time and resource
- Significantly faster alignment on a complex paediatric study design for a multinational paediatric clinical trial: 5-6 months from request to receipt of final advice
- Similar to time needed for consulting with one Agency
- PSA process facilitated detailed understanding of FDA and EMA positions
- Final study design proposal met expectations of both Agencies
Case 1

PSA challenges based on Sponsor feedback

- Trilateral meeting:
  - Careful preparation is key
  - Challenging to discuss all topics, prioritisation needed
  - Advisable to provide written answers to all issues prior to the meeting
  - Separate preliminary feedback from FDA and EMA at different time points
  - Limited time (approx. 1 week) to prepare slide presentation
- Preference to receive FDA/EMA consolidated feedback or separate feedback but at a similar time point
- Detailed work on trilateral meeting presentation and written answers is key
Case 1

Sponsor perception

- PSA very helpful to get alignment from FDA and EMA expeditiously when a significant change to the previously agreed clinical paediatric strategy was proposed
- Allows for detailed understanding of FDA and EMA thinking
Case 1

FDA and EMA perception

- PSA worked well to agree on strategy in a rare paediatric population
- Provided a good basis for further separate discussion on detailed protocol
- Challenges mentioned by the Sponsor are acknowledged
- Receiving separate preliminary feedback may however facilitate a clear understanding of each Agency’s position when preparing the trilateral meeting
Background and PSA request letter

- Gene therapy medicinal product (ATMP)
  - Haematopoietic stem and progenitor cells (HSPC) transduced ex-vivo by a gene carrying lentiviral vector for treatment of an enzyme deficiency syndrome
- Orphan designation in US and EU
- Scope: all areas of development (CMC/NC/Clin)
- Ultra-rare population
- Focus on CMC requirements and design of a single pivotal clinical study
- Ensure regulatory alignment before initiation of the single pivotal trial
- Earlier development had been discussed previously with FDA and EMA
- Sponsor informally explored PSA options with both Agencies
Case 2

PSA request letter

- Sponsor suggested handling of CMC questions in writing given the high number of questions
- Clear indication of Questions addressed to both FDA and EMA and few Questions to either Agency addressing region specific considerations
- Envisaged procedural timelines indicated facilitating efficient procedural planning
Questions raised - CMC

- Drug substance manufacturing
- Comparability assessment for new manufacturing process
- Batch analysis and stability data for lentiviral vector use
- Product release specifications
- Potency assay
Questions raised – Non-Clinical and Clinical

• Overall non-clinical strategy

• Design of a single pivotal Phase 3 study:
  - general design principles: single arm design, use of historic controls
  - study population
  - primary and secondary efficacy endpoints
  - composition of historical comparator cohort
  - statistical analysis plan
Questions to EMA

• Suitability of envisaged evidence generation to demonstrate ‘Significant Benefit’ in the context of the EU Orphan Designation
• Paediatric development plan

Question to FDA

• Considerations on eligibility for Rare Pediatric Disease Product Application
Case 2

EMA working parties/committees/patients

- Scientific Advice Working Party (SAWP) as procedure lead
- Committee for Advanced Therapy Medicinal Products (CAT)
- Paediatric Committee (PDCO)
- Committee for Orphan Medicinal Products (COMP)
- Biologics Working Party (BWP) for CMC aspects
- Committee for Medicinal Products for Human Use (CHMP) adopted the final letter
- Two patient representatives
Case 2

First PSA to discuss ATMP related CMC aspects

- CMC topics acceptability explored informally before request
- Option considered during a ATMP cluster meeting and welcomed
- During PSA, CMC aspects were discussed in separate bilateral meeting
- Main bilateral meeting focused on non-clinical and clinical issues
- There was good agreement on CMC aspects between Agencies’ experts
- CMC Questions could be included for discussion at the trilateral meeting, but this was not required here
- FDA and EMA CMC experts considered discussions helpful and welcome future opportunities to discuss CMC aspects of complex products/ATMPs as part of formal PSA
Conclusion

• PSA is a useful and efficient way to align complex global development programmes
  • Innovative products
  • Areas with lacking/diverging regulatory guidance
  • Products targeting challenging populations
• Informal conversations with FDA and EMA contact points/International Offices can be helpful to prepare a PSA request
• PSA General Principles provide necessary information for efficient planning
• Timelines are met
• Increasing number of PSA procedures suggest an increasing appreciation by Sponsors as well as EMA and FDA experts
Considering a PSA Request?

Summary and Best Practices

Sandra L. Kweder, MD
Deputy Director, Europe Office
Office of Global Policy and Strategies
US Food and Drug Administration
Challenge Question 1

When EMA and FDA consider whether to grant a PSA request, they consider which of the following factors?

A. Public health benefit of the product
B. Likely cost of the product being developed
C. Potential to address unmet medical need
D. How easy the product is to manufacture
E. A and C
F. All of the above
Challenge Question 2

What percentage of all PSA requests from 2016-2020 were accepted by both Agencies?

A. 25%
B. 42%
C. 58%
D. 70%
Parallel Scientific Advice

**PSA 101**

**It Is**

- Scientific advice on product development to support a global program
- Mechanism that brings two regulators to the table simultaneously
- Opportunity to learn how aligned they are

**It Is Not**

- Guarantee of FDA and EMA alignment
- A substitute for sound scientific planning
- The end of the story

General Principles for PSA document [https://www.fda.gov/media/105211/download](https://www.fda.gov/media/105211/download)
Myths abound

- Timelines are within expected for similar processes
- Most variability in timelines depends on applicants and how long it takes between initial inquiry and a sound briefing book
- Once the process is underway you will be able to predict when you will have your advice
Experience tells the story

• PSA is a “work up front” process
• Prepared sponsors have the best experience
  – Data backs up proposals
  – Seek to foster discussion
  – Prepared to expand thinking
• Prepared agencies have good experiences
  – Informed, thoughtful experts
  – Work through internal differences ahead of meeting
• Rewarding experience for sponsors, EMA and FDA
Best Practices 1

Timing matters

• PSA should not be your first discussion with FDA on development
  – Prior pre-IND or IND
  – Allows PSA to focus on global development

• Factor in calendar
  – Agencies’ timelines reliable
  – Expect 2 weeks to reply to informal request
  – August recess of SAWP
Best Practices 2
Best candidates

• Check FDA and EMA guidelines
  • If agencies already aligned PSA may not have added value
• Best candidates
  • Innovative products
  • New science
  • Novel regulatory concepts
Best Practices 3
Make the case for public health value

- Unmet medical need
- Rare diseases
- Special populations
- Explain product potential
- Be specific!
Best Practices 4

Briefing materials

• Single book for both agencies essential
  • CHMP Scientific Advice template
• Be clear on priorities
• Think through issues and options – then be candid about plans
• Label questions for one agency or both
Best Practices 5:
The Trilateral Meeting

• Prepare well
• Use preliminary feedback
• Prioritize
• Foster discussion
• Prepare your whole team